_
Alzheimer's cure: World General Media News Headlines
Alzheimer's treatment: World General Media News Headlines
Alzheimer theories: World General Media News Headlines
Alzheimer science professional news: Alzforum News & Views
March 04, 2006
Experimental Alzheimer’s Drug curbs the disease in mice, UCI's LaFerla research says
Frank LaFerla, a professor of neurobiology at the University of California, Irvine (UCI) and also the senior author in the research said that the experimental drug AF267B is effective against both forms of brain lesions found in Alzheimer's disease in mice. This compound (AF267B) curbs both the amyloid protein plaques that collect in Alzheimer's-affected brains, as well as another lesion, the tangles of protein called tau. In mice that have been genetically designed to mimic Alzheimer's disease AF267B also appears to reverse cognitive declines. Researchers said that the mice appeared to gain renewed powers of memory and learning after treatment. The findings of the study were reported in the journal Neuron. AF267B is a perfect drug for the Alzheimer's disease. It has the disease-modifying capacity that treats the symptoms and also reverses the cognitive declines. Frank LaFerla said that AF267B is an M1 agonist. It acts by stimulating the muscarinic receptor which is present on the surface of nerve cells. In the Alzheimer's disease there is a selective loss of neurons which produce the neurotransmitter acetylcholine. He said that by stimulating the M1 receptor one can boost the acetylcholine activity and AF267B does the stimulation. It was developed by the famous Alzheimer's researcher and study co-author Abraham Fisher, of the Israel Institute for Biological Research, in Ness-Ziona, Israel.
Source: MedIndia.com (2 March 2006) [FullText]
Source: MedIndia.com (2 March 2006) [FullText]
posted by Dr. Koudinov @ 4.3.06
Latest PubMed 20 review articles on Alzheimer’s
Latest PubMed 20 research articles on Alzheimer’s amyloid
Latest PubMed 50 research titles on Alzheimer’s
0 Comments:
Post a Comment
<< Home